Form 4: Provectus Biopharmaceuticals CEO Acquires Convertible Promissory Note and Preferred Stock

Edward Pershing, CEO of Provectus Biopharmaceuticals, acquired an 8% unsecured convertible promissory note and Series D-1 Convertible Preferred Stock, according to a recent SEC Form 4 filing.

Summary

• Edward Pershing, the CEO of Provectus Biopharmaceuticals, filed a Form 4 with the SEC.
• The filing details the acquisition of an 8% unsecured convertible promissory note with a value of $125,000 on February 20, 2025.
• The note is convertible into Series D-1 Convertible Preferred Stock at a price of $2.862 per share.
• Pershing also beneficially owns 43,676 shares of Series D-1 Convertible Preferred Stock.
• Each share of Series D-1 Preferred Stock is convertible into 10 shares of common stock.
• The Series D-1 Preferred Stock will automatically convert into common stock on June 26, 2026, unless converted earlier.
• The promissory note will automatically convert into Series D-1 Preferred Stock twelve months after the issue date.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing insider transactions, which is neither inherently positive nor negative.

Future Outlook

The Series D-1 Preferred Stock will automatically convert into Common Stock on June 26, 2026, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Preferred Stock.

Industry Context

This filing is a routine disclosure related to insider transactions and is common in the biopharmaceutical industry.

Stakeholder Impact

• The acquisition of convertible securities by the CEO could be viewed positively by shareholders as it aligns management's interests with the company's success.

Key Dates